文献速递胸部肿瘤

现代保肺三联疗法改善恶性胸膜间皮瘤患者结局

Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.
PubMed 文献 · J Thorac Oncol · 2017-03-21

该研究比较了恶性胸膜间皮瘤患者接受胸膜切除/剥脱术后辅助化疗联合半胸调强胸膜放疗(IMPRINT)与既往常规放疗(CONV)的疗效。结果显示IMPRINT组中位总生存期显著高于CONV组(20.2个月 vs 12.3个月,p=0.001),且≥2级食管炎发生率更低(23% vs 47%)。

要点

  • IMPRINT组中位OS为20.2个月,CONV组为12.3个月,差异显著(p=0.001)。
  • IMPRINT组≥2级食管炎发生率为23%,CONV组为47%。
  • 多因素分析显示较高的Karnofsky体能评分、上皮样组织学类型、肉眼完全切除及使用化疗/IMPRINT是更长OS的显著因素。

核心结论

  • 包含辅助半胸IMPRINT、化疗和胸膜切除/剥脱术的三联疗法与有前景的总生存率及更低的毒性相关。
  • 应警惕地应用剂量约束以尽量减少严重不良事件。

研究设计与样本

  • 研究分析了1974年至2015年间接受胸膜切除/剥脱术和辅助放疗的209例恶性胸膜间皮瘤患者,其中131例接受常规放疗(CONV),78例接受半胸调强胸膜放疗(IMPRINT)。
  • 主要终点为总生存期(OS),采用Kaplan-Meier法和Cox比例风险模型计算OS,局部无失败生存和进展无生存采用竞争风险分析。
  • 进行了单因素和多因素分析,纳入相关临床和治疗因素。

主要发现

  • 患者中位年龄为64岁,80%为男性。
  • 接受IMPRINT的患者具有显著更高的上皮组织学类型、晚期病理分期和化疗治疗比率。
  • IMPRINT组中位OS显著更高(20.2个月 vs 12.3个月,p=0.001)。
  • 多因素分析显示较高的Karnofsky体能评分、上皮样组织学类型、肉眼完全切除以及使用化疗/IMPRINT是更长OS的显著因素。
  • 未发现局部失败或进展的显著预测因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Higher target conformity and better sparing of organs at risk with modern radiotherapy (RT) may result in higher tumor control and less toxicity. In this study, we compare our institutional multimodality therapy experience of adjuvant chemotherapy and hemithoracic intensity-modulated pleural RT (IMPRINT) with previously used adjuvant conventional RT (CONV) in patients with malignant pleural mesothelioma (MPM) treated with lung-sparing pleurectomy/decortication (P/D). METHODS: We analyzed 209 patients who underwent P/D and adjuvant RT (131 who received CONV and 78 who received IMPRINT) for MPM between 1974 and 2015. The primary end point was overall survival (OS). The Kaplan-Meier method and Cox proportional hazards model were used to calculate OS; competing risks analysis was performed for local failure-free survival and progression-free survival. Univariate analysis and multivariate analysis were performed with relevant clinical and treatment factors. RESULTS: The median age was 64 years, and 80% of the patients were male. Patients receiving IMPRINT had significantly higher rates of the epithelial histological type, advanced pathological stage, and chemotherapy treatment. OS was significantly higher after IMPRINT (median 20.2 versus 12.3 months, p = 0.001). Higher Karnofsky performance score, epithelioid histological type, macroscopically complete resection, and use of chemotherapy/IMPRINT were found to be significant factors for longer OS in multivariate analysis. No significant predictive factors were identified for local failure or progression. Grade 2 or higher esophagitis developed in fewer patients after IMPRINT than after CONV (23% versus 47%). CONCLUSIONS: Trimodality therapy including adjuvant hemithoracic IMPRINT, chemotherapy, and P/D is associated with promising OS rates and decreased toxicity in patients with MPM. Dose constraints should be applied vigilantly to minimize serious adverse events.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Shaikh F, Zauderer MG, von Reibnitz D, et al. Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma. J Thorac Oncol. 2017. PMID: 28341225. doi:10.1016/j.jtho.2017.02.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。